1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A

TTWSE:1762
33.60
TWD
-0.75
(-2.18%)
-0.85EPS
2.85BMarket Cap
Nov 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
13.45
12.21
14.98
15.45
15.06
13.14
14.91
19.9
24.94
27.3
26.9
24.07
14.48
15.39
Basic EPS, GAAP
1.25
0.19
3.98
0.78
1.11
3.02
1.51
6.86
5.17
6.01
3.42
0.95
-4.39
-0.85
Free Cash Flow per Basic Share
0.45
-1.59
-0.64
1.89
-8.33
1.82
1.98
-0.71
-2.4
4.61
-6.68
6.48
1.44
4.09
Dividend per Share
1.59
1
0.5
1.5
0.5
0.5
1.2
0.8
1.5
1.3
1.3
1.11
0.27
- -
Book Value per Share
21.29
20.26
23.67
22.83
23.48
25.58
25.98
32.21
37.31
41.17
43.2
43.28
40.14
41.64
Tangible Book Value per Share
21.29
20.24
23.65
22.83
23.44
25.55
25.96
32.2
37.29
41.07
43.12
43.23
40.12
41.63
Basic Weighted Avg Shares
78
78
78
78
78
78
78
78
78
78
78
56
56
61
Sales/Revenue/Turnover
1,043
947
1,162
1,199
1,168
1,019
1,157
1,544
1,935
2,117
2,086
1,347
805
934
Operating Margin (%)
9.46
2.47
8.56
8.19
6.69
3.03
10.47
17.42
23.61
21.03
13.46
0.47
-39.7
-14.61
Depreciation Expense
83
96
103
115
134
135
130
131
132
169
193
199
191
186
Net Income, GAAP
97
15
308
60
86
234
117
532
401
466
265
53
-244
-52
Effective Tax Rate (%)
14.75
60.66
8.27
35.35
21.59
2.48
18.52
18.18
19.41
20.09
20.56
7.32
- -
- -
Profit Margin (%)
9.28
1.54
26.53
5.03
7.34
22.98
10.12
34.46
20.72
22
12.7
3.94
-30.3
-5.53
Working Capital
136
541
229
117
219
188
111
601
722
835
956
1,016
702
870
LT Debt
540
650
130
100
567
567
603
1
601
501
704
704
603
602
Total Equity
1,711
1,616
1,864
1,771
1,821
1,984
2,015
2,499
2,894
3,193
3,350
3,357
3,087
3,203
Return on Invested Capital (%)
3.24
0.34
3.49
2.67
2.3
1.04
3.45
7.95
11.24
9.84
5.3
0.13
- -
- -
Return on Capital (%)
4.14
0.73
12.18
2.75
3.48
8.45
4.41
19.78
13.11
12.72
6.71
1.66
- -
- -
Return on Common Equity (%)
5.86
0.91
18.1
3.34
4.78
12.31
5.85
23.57
14.86
15.31
8.1
1.58
-7.57
-1.6

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
203
202
154
LT Borrowings
600
600
600
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
77
77
77
Market Capitalization
1,884
2,204
2,854

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,059
1,211
1,154
Cash, Cash Equivalents & STI
216
286
330
Accounts Receivable, Net
92
201
155
Inventories
718
680
635
Total Current Liabilities
357
402
284
Payables & Accruals
- -
- -
- -
ST Debt
203
202
154
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.56%
4.65%
-8.03%
Free Cash Flow
-173.01%
-108.9%
-77.88%
Net Income, GAAP
-25.19%
-138.27%
-559.81%
Sales/Revenue/Turnover
-0.76%
-8.47%
-40.26%
Total Cash Common Dividend
- -
- -
-76.25%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
252
461
348
286
1,347
2025
193
344
154
113
805
2026
361
305
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.52
0.27
-0.11
- -
0.95
2025
0.13
-0.88
-0.77
-1.84
-4.39
2026
1.64
0.75
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.11
2025
- -
- -
- -
- -
0.27
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chung Hsin Huang
Full Time Employees
243
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
No.1, Dongxing Street New Taipei TP Taiwan 23850
IPO Date
Dec 10, 2009
Website
ccsb.com.tw
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) manufactures and sells active pharmaceutical ingredients (APIs) for the global pharmaceutical industry. The company produces a wide range of biotech and chemical synthetic products, including immunosuppressants such as tacrolimus, everolimus, rapamycin and mycophenolate mofetil; antifungals such as fluconazole, caspofungin and anidulafungin; cardiovascular drugs such as pravastatin, trandolapril and edoxaban tosylate monohydrate; oncology agents; pain management products including methocarbamol and skeletal muscle relaxants; antidiabetics such as glipizide; antihistamines like olopatadine and dexbromopheniramine maleate; anti-anxiety agents; laxatives; antiseptics; antiulcerants; hypolipidemics; antineoplastics; antihyperlipidemics; peptide drugs such as abaloparatide; anti-virus agents; immunomodulating agents including baricitinib and eltrombopag olamine; and others such as guaifenesin, eslicarbazepine acetate, brivaracetam, difelikefalin acetate and sugammadex sodium. It operates cGMP-compliant facilities approved by the FDA and EU, provides contract manufacturing and research services, and distributes products domestically in Taiwan and internationally to Asia, the Americas and Europe. Founded in 1964 and headquartered in New Taipei City, Taiwan, the company maintains a manufacturing site spanning 8.7 acres in the Taipei suburb and employs approximately 243 people. In recent developments, Chunghwa Chemical Synthesis & Biotech successfully completed multiple customer audits in 2025, including those for ethyl icosapentate and everolimus in September, sugammadex sodium in August, tacrolimus in May from an Indian client, caspofungin and trandolapril in May from a Greek client, rapamycin in April from a Japanese client, and mycophenolate mofetil in April and March from Indian clients; it also authorized a share buyback plan in April 2025 and received the 2025 Corporate Sustainability Report Award in November.